source
- Novo signs $1.3 billion deal with Nanexa to add long-acting injectables for obesity and diabetesNovo has entered a licensing agreement with Nanexa, valued at about 1.17 billion euros, to use Nanexa’s PharmaShell platform for its obesity and type‑2 diabetes medicines. The PharmaShell technolo…
- Genentech signs $1.5 billion bispecific antibody deal with Earendil LabsGenentech, Roche's US subsidiary, announced a licensing agreement with Earendil Labs to discover and develop multiple bispecific antibodies aimed at oncology. The agreement provides a $55 million…